SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TITAIN TRIAL

Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, Mendelson M, Sieder C, Maricos M, Thiel J (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Annals of the Rheumatic Diseases BMJ Publishing Group

Publisher: BMJ PUBLISHING GROUP

City/Town: LONDON

Pages Range: 121-122

Conference Proceedings Title: ANNALS OF THE RHEUMATIC DISEASES

DOI: 10.1136/annrheumdis-2022-eular.806

Authors with CRIS profile

Hans Jürgen Rech Department of Medicine 3 – Rheumatology and Immunology

Involved external institutions

Albert-Ludwigs-Universität Freiburg DE Germany (DE) Immanuel Krankenhaus Berlin DE Germany (DE) Klinikum der Stadt Ludwigshafen am Rhein gGmbH DE Germany (DE) Krankenhaus Dresden-Friedrichstadt, Städtisches Klinikum DE Germany (DE) Universitätsklinikum Würzburg DE Germany (DE) Novartis AG CH Switzerland (CH)

How to cite

APA:

Venhoff, N., Schmidt, W.A., Bergner, R., Rech, J., Unger, L., Tony, H.P.,... Thiel, J. (2022). SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TITAIN TRIAL. In ANNALS OF THE RHEUMATIC DISEASES (pp. 121-122). LONDON: BMJ PUBLISHING GROUP.

MLA:

Venhoff, N., et al. "SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TITAIN TRIAL." Proceedings of the ANNALS OF THE RHEUMATIC DISEASES LONDON: BMJ PUBLISHING GROUP, 2022. 121-122.

BibTeX: Download